Jubilant Pharmova Limited Valuation
JUBLPHARMA · Healthcare · Current price ₹933.5
Is Jubilant Pharmova Limited undervalued?
We estimate the fair value of Jubilant Pharmova Limited at ₹320 per share, against a market price of ₹1,025. That puts the share price about -68.8% above our estimate, at low confidence. This is our view of what the business is worth, not a target price or a forecast of where the share price will go.
How this fair value is calculated
This estimate comes from 1 method: Fair multiple (P/E) (₹320). Each is weighted by how well its inputs held up for this company. The full working, including the assumptions and what data was missing, is set out below.
The range around this estimate
Our estimate for Jubilant Pharmova Limited spans ₹288 to ₹352. That range is wide, which is the honest signal here: read the range rather than the single number. A margin of safety means buying meaningfully below the estimate: the wider the range, the more room the assumptions leave for error.
Valuation multiples
Jubilant Pharmova Limited trades at a P/E of 37.1x and a P/B of 2.3x, with a dividend yield of 0.5%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
How we got this fair value
Every number below is part of the same estimate for Jubilant Pharmova Limited. Nothing here is a target price or a forecast of where the share price will go.
The inputs are thin or the models disagree sharply. This is our least reliable kind of estimate, so read the range rather than the single number.
Estimate range ₹288 – ₹352
Why this method for this business
Relative P/E is appropriate for a pharmaceutical company with stable earnings and a narrow moat, while EV/EBITDA captures capital intensity and debt structure.
The models behind the number
Each method is weighted by how well its inputs held up for this company.
required inputs missing
- dcf: Not suitable for a cyclical and capital-intensive business with erratic earnings
- fair multiple (P/E): Already used in relative PE model
What was missing
- Lack of forward EPS estimates
- Limited analyst coverage
- Uncertainty in regulatory environment
What drives it
16 inputs, grouped by how strong each claim is
- Sector-median P/E
- 38.15×
- Peers used
- 42
- EPS (TTM)
- 22.11 ₹/share
- Own-history median P/E
- 17×
peer-median
peer-median
computed
reconstructed (one feature, dampened — not a cap)
- Anchor correction
- peer anchor 38.2x diverges 0.4x from 5yr own-history 17.0x (no size-comparable peer) — anchor blended 0.6 toward own-history → 25.5x
- Term: quality
- -11.9%
- Term: growth
- -29.4%
- Term: capital_allocation
- -7.1%
- Term: financial_strength
- +7.9%
- Term: history
- -10.0%
- Term: sector_rerating
- +0.0%
- Term: rate_regime
- +1.2%
- Term: risk
- +0.0%
peer-anchor mismatch — deep own-history used instead
quality 31/100 (weak/erratic returns) → discount
weak ~-4% CAGR (ROCE 12% > hurdle) → discount
capital allocation: falling ROCE / weak cash generation → discount
financial strength: effectively debt-free → premium
history: market paid -33% vs sector, dampened ×0.3 (one feature, not the anchor)
sector re-rating: no sector-norm history → not used
rates: risk-free 6.9% below ~7.1% normal → higher multiple
risk: no analyst-dispersion signal available → neutral (lowers confidence, not PE)
- Premium vs sector
- -43.2%
- Fair-multiple confidence
- 82%
- Fair P/E
- 14.46×
fundamentals + macro (not capped at own history)
data completeness + term agreement
sector median × ∏(1+term) — Dynamic Fair Multiple
Who computed this
A language model (qwen3:8b) selects the valuation method and the judgement inputs for Jubilant Pharmova Limited: which models suit the business, the moat, the growth and margin assumptions. It does not produce the number. The fair value itself is computed in Python by a deterministic engine (version 2026.08.1) from those inputs, so the same inputs always give the same result and every figure above can be traced to a source.
Estimated 14 Sept 2026. Re-run as new financials and news arrive.
How we value stocks
We estimate what a business is worth from its own economics: cash flows, returns on capital, and a multiple justified by its quality, rather than from where the share price has been. A fair value estimate is a view, not a verdict, and it is only as good as the inputs listed above.
Read the full fair-value methodologyUnderstand the ratios
More on Jubilant Pharmova Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.